This study was designed to clarify whether gene expression in the cardiac sarcoplasmic reticulum [sarcoplasmic reticulum Ca 2 + -ATPase (SERCA), phospholamban, ryanodine receptor and calsequestrin] changes in accordance with left ventricular functional alterations in the volumeoverloaded heart. Further, the effect of the angiotensin II type 1 receptor antagonist, TCV-116, on the expression of these genes was also evaluated. Left ventricular fractional shortening was significantly increased at 7 days, had returned to control levels at 21 days, and had significantly decreased at 35 days after the shunt operation, compared with sham-operated rats. The level of SERCA mRNA was significantly decreased at both 21 days and 35 days after the shunt operation. The levels of ryanodine receptor and phospholamban mRNAs were significantly decreased at 35 days in shunt-operated rats. The decrease in the SERCA mRNA level preceded the development of cardiac dysfunction. The levels of SERCA and ryanodine receptor mRNAs were correlated positively with left ventricular fractional shortening (r l 0.73, P 0.0001 and r l 0.61, P 0.01 respectively). Attenuation of the decrease in left ventricular fractional shortening occurred on treatment with TCV-116. After the treatment with TCV-116, the levels of SERCA and phospholamban mRNAs were restored to the respective values in sham-operated rats. Ryanodine receptor mRNA levels remained unchanged after treatment with TCV-116. These results indicate that the down-regulation of SERCA and ryanodine receptor mRNA levels may be related to cardiac dysfunction in the volume-overloaded heart. In addition, treatment with an angiotensin II receptor antagonist may restore the altered sarcoplasmic reticulum mRNA levels to control levels, and this may result in attenuation of the functional impairment in the volumeoverloaded heart.
INTRODUCTION
The cardiac sarcoplasmic reticulum (SR) plays an important role in the contraction\relaxation cycle of the Dephosphorylated phospholamban decreases the affinity of SERCA for Ca# + , and phosphorylation relieves this inhibitory effect. The ryanodine receptor (RYR) initiates the contraction of cardiomyocytes by releasing Ca# + from the SR. Calsequestrin is the major Ca# + -storage protein, which reduces the luminal concentration of free Ca# + and facilitates further uptake of Ca# + by SERCA.
Chronic pressure overload causes concentric hypertrophy and dysfunction in the left ventricle. Some reports have shown that down-regulation of SERCA gene expression occurs in pressure-overloaded concentric hypertrophy [5, 6] , and that this down-regulation is correlated with the cardiac dysfunction [7] . On the other hand, it has been reported that volume overload associated with an arteriovenous fistula causes eccentric cardiac hypertrophy and cardiac dysfunction [8, 9] . However, it remains unknown whether the alterations in SR gene expression observed in eccentric hypertrophy are identical with those present in pressure-overloaded concentric hypertrophy.
Some clinical trials have shown that treatment with angiotensin II receptor antagonists improves left ventricular function in patients with heart failure [10, 11] . Experimental studies have also shown that cardiac dysfunction is improved by chronic treatment with angiotensin II receptor antagonists [12, 13] . In addition, Flesch et al. [14] have shown that an improvement in left ventricular diastolic function in pressure-overloaded hearts treated with an angiotensin II receptor antagonist was related to the restoration of decreased myocardial SERCA mRNA levels. However, it remains unknown whether functional improvements occur on treatment of volume-overload hypertrophy with angiotensin receptor antagonists and, if so, whether these improvements are correlated with altered SR gene expression.
Thus we examined whether changes in left ventricular function are related to the altered expression of SR genes in the rats with volume-overload hypertrophy, and also examined how this relationship is modified by chronic treatment with an angiotensin II receptor antagonist.
METHODS

Left ventricular volume-overload model
Male Sprague-Dawley rats (Charles River, Atsugi, Kanagawa, Japan) aged 8 weeks were used. All operative procedures were carried out following the intraperitoneal administration of pentobarbital sodium (40 mg\kg). Left ventricular volume overload in rats was induced using the procedures described by Garcia and Diebold [15] . A 20-mm segment of abdominal aorta was exposed through a mid-abdominal incision. An arteriovenous fistula between the abdominal aorta and the inferior vena cava was made using an 18-gauge disposable needle. Swelling of the vena cava and mixing of arterial blood with venous blood were used as evidence for the patency of the fistula. Sham-operated rats acted as controls ; procedures were identical with those for the arteriovenous shunt rats, except that a fistula was not inserted. All rats were given food and water ad libitum, and kept on a 12-h light\dark cycle. Animal care and experimental procedures were conducted in accordance with the Guidelines for Animal Research of Ehime University.
Experimental protocol
To assess the time course of haemodynamic changes due to volume overload, the shunt and sham-operated rats were examined on days 7, 21 and 35 after the operation. After the evaluation of haemodynamic parameters and cardiac geometry using cardiac catheterization and echocardiography as described below, the heart was rapidly excised and weighed. Using total RNA extracted from the left ventricle of each sample, SERCA, phospholamban, RYR and calsequestrin mRNA levels were assessed by Northern blot analysis.
To evaluate the effects of an angiotensin II receptor antagonist on left ventricular functional changes and SR gene expression in volume-overloaded hearts, the shunt rats at 35 days post-operation were divided into two groups : group T (TCV-116) and group V (vehicle). A novel orally active angiotensin II type 1 receptor antagonist, TCV-116 (provided by Takeda Chemical Industries, Ltd., Osaka, Japan), was given by oral gavage (10 mg\kg per day in 1 ml of 5 % gum arabic) once a day. The rats in group V were treated with vehicle. After drug administration, systolic blood pressure was determined once a week by the tail cuff method [16] . After treatment for 35 days, the same procedures were performed as described above.
Echocardiographic evaluation
Echocardiographic studies were performed with a 7.5 MHz sector scan probe (model SSH-140A ; Toshiba) as described by Okayama et al. [17] . All rats were lightly anaesthetized with 15 mg\kg pentobarbital (intraperitoneal), and the chest was shaved. Then the rat was placed in the left lateral decubitus position and a transducer, focused on 7 mm, was placed on the chest. An M-mode echocardiogram was determined at the papillary muscle level, guided by a two-dimensional echocardiogram, and was recorded at a paper speed of 100 mm\s (model TP 8700 ; Toshiba). Left ventricular dimensions were determined from the mean value of three successive beats according to the method of the American Society of Echocardiography [18] . Left ventricular fractional shortening (LVFS) was calculated using the following formula :
where LVDD and LVDS are the left ventricular enddiastolic and end-systolic dimensions.
Cardiac catheterization
After the echocardiographic survey, a PE-50 catheter (Clay Adams, Parsippany, NJ, U.S.A.) filled with heparinized (100 units\ml) saline was inserted into the left ventricle via the right common carotid artery. The catheter was exteriorized on the neck of the animal, and the left ventricular peak systolic pressure, the left ventricular end-diastolic pressure, and the maximum value [(dP\dt) max ] and minimum value [(kdP\dt) min ] of the rate of change in left ventricular pressure were assessed as described in [19] .
Left ventricular mass (LVM) index
After body weight had been measured under pentobarbital anaesthesia, the chest cavity was opened. The heart was rapidly excised, and placed into ice-cold saline to remove the blood. After removal of the atria and large vessels, the ventricles were blotted dry and the right ventricle was dissected along its septal insertion and, finally, the weight of left ventricle was assessed. The LVM index was calculated using the following formula :
The left ventricle was immediately put into liquid nitrogen and stored at k80 mC until used.
Northern blot analysis
Total RNA was extracted from each tissue sample by a modified version of the acid guanidinum isothiocyanate\ phenol\chloroform method, using a commercially available kit (Isogen ; Nippon Gene Co. Ltd, Tokyo, Japan). For Northern blot analysis, 20 µg of total RNA was denatured at 65 mC for 15 min in 2.2 µmol\l formaldehyde and 50 % deionized formamide, and electrophoresed through a 1.0 % (w\v) agarose gel containing 2.2 mol\l formaldehyde at 60 V. Then, RNA was transferred to a nylon membrane (Hybond N + ; Amersham) by vacuum blotting after staining with ethidium bromide to verify the relative quantity and quality of RNA. The RNA bound on the filter was fixed according to the manufacturer's protocol. Prehybridization and hybridization of the filter were performed using commercial buffer (QuickHyb Hybridization Solution ; Stratagene Cloning System, La Jolla, CA, U.S.A.). The conditions of prehybridization, hybridization and washes of the filter followed the manufacturer's protocol. After high-stringency washing, blots were exposed to an X-ray film (Hyperfilm-MP ; Amersham Co. Ltd., Tokyo, Japan) with an intensifying screen at k80 mC for 24 h.
For the quantitative measurement of hybridized signals, the membrane was exposed to an imaging plate and analysed using a Bio-Imaging Analyzer BAS 1000 (Fuji Film Co. Ltd., Kanagawa, Japan). The level of expression of each mRNA was normalized by reference to that of 28 S rRNA, and finally expressed in mean arbitrary units relative to that in sham-operated groups (which was set to unity). For the quantification of the 28 S rRNA, photographic images of the ethidium bromide-stained gel were computerized by a CCD camera, and the intensity of the 28 S rRNA band was determined using NIH image 1.59 software (National Technical Information Service, Springfield, VA, U.S.A.).
The following cDNA probes were used for Northern blot analysis : rat SERCA cDNA, nucleotides 1092-2070 [20] ; mouse phospholamban cDNA, nucleotides k172 to 632 [21] ; canine cardiac calsequestrin cDNA, nucleotides 304-1243 [22] ; rabbit cardiac RYR cDNA, nucleotides 4868-5480 [23] . Fragments, synthesized by reverse transcriptase-polymerase chain reaction, were subcloned into pBluescript II (Stratagene) and then subjected to sequence analysis using the dideoxy method. Each cDNA probe was labelled with [α-$#P]dATP using a random primer DNA labelling kit (Prime-It II ; Stratagene).
Statistical analysis
All values are expressed as meanspS.E.M. Comparisons among three or more groups were made using one-way ANOVA followed by Scheffe! s multiple-range tests. Correlations between two variables were examined by linear regression analysis. A value of P 0.05 was considered statistically significant.
RESULTS
LVM index
The LVM index at 7, 21 and 35 days after the operation was significantly greater, by 21 %, 34 % and 42 % respectively, in shunt-operated rats compared with shamoperated rats (P 0.001 ; Table 1 ).
Left ventricular functional and geometric changes
LVDD was significantly greater in shunt-operated rats than in sham-operated rats at all time points after the operation (Table 1) . LVFS was greater in shunt-operated than in sham-operated rats at 7 days after the operation. At 21 days post-operation there was no significant difference in LVFS between the two groups. At 35 days post-operation, however, LVFS was significantly lower in shunt-operated than in sham-operated rats. The values The level of expression of each mRNA was normalized with respect to that of 28 S rRNA, and is expressed in arbitrary units ; the mean value for sham-operated rats was set to unity in each case. Values are expressed as meanspS.E.M. (A) SERCA, (B) phospholamban, (C) RYR, (D) calsequestrin. The significance of differences between means is indicated ; N.S., not significant.
of (dP\dt) max and (kdP\dt) min showed no significant differences between shunt-and sham-operated rats at 7 and 21 days post-operation. However, at 35 days postoperation, these values were significantly lower in shuntoperated than in sham-operated rats. The left ventricular peak systolic pressure showed no significant difference between shunt-and sham-operated rats at all times ( Table  1) . The left ventricular end-diastolic pressure was significantly higher in shunt-operated than in sham-operated rats at all times (Table 1) . Sarcoplasmic reticulum gene in cardiac hypertrophy 
Alterations in gene expression of SR proteins
As shown in Figure 1 (A), SERCA mRNA levels were decreased in shunt-operated rats by 14 % at 21 days and by 20 % at 35 days post-operation compared with shamoperated rats. Phospholamban ( Figure 1B ) and RYR ( Figure 1C ) mRNA levels remained unchanged at 7 and 21 days post-operation, but were significantly lower after 35 days in shunt-operated rats than in sham-operated rats (34 % and 29 % respectively). Calsequestrin mRNA levels ( Figure 1D ) showed no significant differences between shunt-and sham-operated rats at all times.
Effect of an angiotensin II receptor antagonist
As shown in Table 2 , the LVM index was significantly lower in rats treated with TCV-116 (group T) than in controls (group V).
LVDD was significantly greater in group V than in group T, and LVFS was significantly greater in group T than in group V. The value of (dP\dt) max was significantly lower in both groups T and V than in sham-operated rats, and there was no significant difference between groups T and V. The value of (kdP\dt) min was significantly lower in both groups T and V than in sham-operated rats, and was significantly greater in group T than in group V.
Systolic blood pressure, measured by the tail cuff method during treatment, and left ventricular peak systolic pressure showed no significant differences between group V and sham-operated rats. However, these values were significantly lower in group T than in group V and sham-operated rats at all times of measurement (P 0.001 ; Figure 2 , Table 2 ). Left ventricular end-diastolic pressure was significantly lower in group T than in group V (P 0.05 ; Table 2 ). Figure 3 shows the alterations in gene expression associated with TCV-116 treatment. SERCA mRNA levels in group T were restored to the levels in shamoperated rats, but those in group V were significantly lower than those in sham-operated rats and group T ( Figure 3A) . Phospholamban mRNA levels in group T were also restored to the levels in sham-operated rats. However, levels in group V were lower ( Figure 3B ) than those in sham-operated rats by 27 %. RYR mRNA levels were significantly lower in both groups T and V than in sham-operated rats (by 22 % and 37 % respectively). Calsequestrin mRNA levels showed no significant differences between the groups ( Figure 3D ). Figure 4 shows the relationship between LVFS and levels of SERCA ( Figure 4A ) and RYR ( Figure 4B ) mRNAs in the left ventricles of shunt-operated rats. The levels of 
Relationship between LVFS and mRNA levels of SR proteins
DISCUSSION
The present study has two major findings. First, the expression of SR genes changes along with the alterations in left ventricular function in the chronic volumeoverloaded heart. The down-regulation of SERCA precedes left ventricular dysfunction in this model. In addition, the down-regulation of SERCA and RYR mRNA levels may be related to cardiac dysfunction in the volume-overloaded heart. Secondly, treatment with the angiotensin II receptor antagonist TCV-116 may restore the altered SR mRNA levels to control values, and this may result in attenuation of the functional impairment in the volume-overloaded heart.
Relationship between left ventricular function and SR gene expression in volumeoverload hypertrophy
Cardiac remodelling and dysfunction occurred in our volume-overload model. The LVM index in shuntoperated rats was significantly increased at all times postoperation. LVDD was significantly greater in shuntoperated than in sham-operated rats. In addition, LVDD in shunt-operated rats progressively increased during the study. LVFS in shunt-operated rats was increased significantly at 7 days, had returned to control levels at 21 days and had markedly decreased at 35 days compared with that in sham-operated rats. Thus, in our volume-overload model, left ventricular function changed from a hyperdynamic state into a hypodynamic state.
In the present study, significant changes in mRNA levels in the SR were not observed at 7 days post- operation. Calderone et al. [24] also showed that the level of SERCA mRNA did not change in the early stages of hypertrophy in the volume-overloaded heart. Thus the high LVFS at this stage in shunt-operated rats may not be due to changes in mRNA levels in the SR, but instead may be related to the rapid change in haemodynamics. Huang et al. [25] have shown that total peripheral resistance in a fistula rat model was markedly decreased in the presence of an arteriovenous fistula. Thus the high LVFS in our study may be mainly related to the hyperdynamic state associated with low total peripheral resistance. Shen et al. [26] reported an enhancement of Ca# + cycling activity by the Ca# + pump and the Ca# + channel of the SR as an early response to volume overload, despite there being no alterations in the expression of SERCA genes. A mechanism similar to that reported by Shen et al. [26] may be partly responsible for the high LVFS in our study.
In the advanced stages of hypertrophy (after 21 days post-operation), a decrease in the SERCA mRNA level was followed by progressive left ventricular dysfunction. In addition, at 35 days, the RYR mRNA level was also decreased. Therefore the down-regulation of SERCA and RYR mRNA levels may contribute to the cardiac dysfunction in the advanced stages of hypertrophy in the volume-overload model. Our results are identical with the data of Hisamatsu et al. [27] , which showed that the impairment of SR function preceded the development of cardiac dysfunction in volume-overload hypertrophy.
Phospholamban inhibits the affinity of SERCA for Ca# + . Thus the decrease in phospholamban mRNA levels observed in the late stages of hypertrophy would be expected to result in an improvement in cardiac contractility. However, cardiac contractility was further decreased in the late stages of hypertrophy in this model. Some reports have suggested that the composite changes in SR phospholipids override the regulatory effects of phospholamban on SERCA in the failing heart [28] [29] [30] . Thus, although the decrease in phospholamban mRNA levels may be one of the compensatory mechanisms that would relieve cardiac dysfunction associated with the decrease in SERCA mRNA levels, such a decrease in phospholamban mRNA may have little effect to improve cardiac dysfunction in the current model.
Calsequestrin mRNA levels, which remained unchanged in this model, may not be related to the functional changes in the volume-overloaded heart model. Calsequestrin mRNA levels do not change under various conditions [31] .
Effect of the angiotensin II receptor antagonist
LVDD and the LVM index were significantly lower in rats in group T (treated with TCV-116) than in group V (controls), indicating that treatment with TCV-116 prevented cardiac remodelling. In addition, an attenuation of the decrease in LVFS also occurred in group T. This indicates that treatment with TCV-116 attenuated progressive cardiac dysfunction in this volume-overload model.
Recently, Hajjar et al. [32] have shown that gene transfer of SERCA into phospholamban-overexpressing cardiomyocytes, which show the same abnormalities in calcium handling as are observed in heart failure, can correct these abnormalities. Thus restoration of the decreased expression of SERCA mRNA to control levels after treatment with TCV-116 may be one of the mechanisms for functional improvement in our model. In our study, it remains to be determined whether TCV-116 stimulates the up-regulation of levels of SERCA and RYR mRNAs directly. Reinecke et al [33] have shown a decrease in SERCA mRNA levels in isolated adult rat cardiomyocytes caused by angiotensin II. This finding suggests that blockade of the renin-angiotensin system by an angiotensin II receptor antagonist may directly prevent the down-regulation of SERCA mRNA in cardiac myocytes.
Although there was no statistically significant change, an upward trend was detected in the levels of RYR mRNA after treatment with TCV-116. Thus longer-term treatment may significantly up-regulate RYR mRNA and contribute to the improvement in cardiac function. Rockman et al. [34] have reported that the downregulation of phospholamban mRNA serves as an adaptive mechanism in heart failure. Therefore the up-regulation of phospholamban mRNA after treatment with TCV-116 in our study may be evidence of the improvement in cardiac function.
Study limitations
Our study has a few limitations. First, although we show a good correlation between left ventricular function and the alteration in SR gene expression, we have no direct evidence of a cause-effect relationship between SR function and cardiac function. To elucidate such a relationship, additional experiments need to be performed. These include examining cardiac function in the SERCA2 and\or RYR knockout model, and transferring a SERCA2 gene into our model in an attempt to rescue impaired cardiac function. Secondly, our study indicated that, after treatment with TCV-116, left ventricular function was improved and the down-regulation of SR genes was reversed close to normal levels. However, we cannot exclude an effect of the decrease in blood pressure in this recovery of left ventricular function and SR gene expression. To elucidate the influence of the decrease in blood pressure on the beneficial results after treatment with TCV-116, further studies will be required that use another drug for blood pressure control or a low dose of an angiotensin II receptor blocker that does not alter blood pressure.
